A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib

被引：1
|
作者：
Chen, Kaiyan [1 ,2 ,3 ]
Zhang, Fanrong [1 ,4 ]
Pan, Guoqiang [1 ,2 ,3 ,5 ]
Sheng, Jiamin [1 ,2 ,3 ,5 ]
Ye, Junyi [6 ]
Xu, Yanjun [1 ,2 ,3 ]
Yu, Xiaoqing [1 ,2 ,3 ]
Huang, Zhiyu [1 ,2 ,3 ]
Fan, Yun [1 ,2 ,3 ]
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China
[3] Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China
[4] Zhejiang Canc Hosp, Dept Breast Surg, Hangzhou, Peoples R China
[5] Wenzhou Med Univ, Clin Med Coll 1, Dept Oncol, Wenzhou, Peoples R China
[6] Bioinformat Dept, Burning Rock Biotech, Guangzhou, Peoples R China
来源：
CLINICAL LUNG CANCER | 2021年 / 22卷 / 01期
关键词：
Crizotinib; MET; Non-small-cell lung cancer; RET; Resistance; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; OPEN-LABEL; CARCINOMAS; PHASE-2;
D O I：
10.1016/j.cllc.2020.07.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E1 / E4
页数：4
相关论文
共 32 条
  • [1] The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy
    Wang, Yubo
    Tian, Panwen
    Xia, Lei
    Li, Li
    Han, Rui
    Zhu, Mengxiao
    Lizaso, Analyn
    Qin, Tian
    Li, Min
    Yu, Bing
    Mao, Xinru
    Han Han-Zhang
    He, Yong
    LUNG CANCER, 2020, 146 : 165 - 173
  • [2] A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification
    Sun, Hongna
    Li, Xiaofen
    Dai, Shuang
    Shen, Xudong
    Qiu, Meng
    PRECISION CLINICAL MEDICINE, 2021, 4 (03) : 209 - 214
  • [3] Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib
    Ji, Jingran
    Mitra, Anupam
    Camidge, D. Ross
    Riess, Jonathan W.
    CLINICAL LUNG CANCER, 2021, 22 (06) : E851 - E855
  • [4] Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
    Rosen, Ezra Y.
    Johnson, Melissa L.
    Clifford, Sarah E.
    Somwar, Romel
    Kherani, Jennifer F.
    Son, Jieun
    Bertram, Arrien A.
    Davare, Monika A.
    Gladstone, Eric
    Ivanova, Elena, V
    Henry, Dahlia N.
    Kelley, Elaine M.
    Lin, Mika
    Milan, Marina S. D.
    Nair, Binoj C.
    Olek, Elizabeth A.
    Scanlon, Jenna E.
    Vojnic, Morana
    Ebata, Kevin
    Hechtman, Jaclyn F.
    Li, Bob T.
    Sholl, Lynette M.
    Taylor, Barry S.
    Ladanyi, Marc
    Janne, Pasi A.
    Rothenberg, S. Michael
    Drilon, Alexander
    Oxnard, Geoffrey R.
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 34 - 42
  • [5] The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
    Jori, Balazs
    Voessing, Christine
    Pirngruber, Judith
    Willing, Eva Maria
    Arndt, Kathrin
    Falk, Markus
    Tiemann, Markus
    Heukamp, Lukas C.
    Hoffknecht, Petra
    CURRENT ONCOLOGY, 2023, 30 (10) : 8805 - 8814
  • [6] Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer - Case Report
    Wang, Pascal
    Matton, Lise
    Kebir, Fatima
    Kerrou, Khaldoun
    Dubois, Antonin
    Lacave, Roger
    Cadranel, Jacques
    Fallet, Vincent
    CLINICAL LUNG CANCER, 2022, 23 (08) : E568 - E572
  • [7] Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping
    Ding, Guanggui
    Wang, Jian
    Ding, Peikun
    Wen, Yuxin
    Yang, Lin
    CANCER BIOLOGY & THERAPY, 2019, 20 (06) : 837 - 842
  • [8] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [9] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    Journal of Translational Medicine, 17
  • [10] ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report
    Xu, C.
    Wang, W.
    Song, Z.
    Zhang, Q.
    Zhuang, W.
    Chen, Y.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1032 - S1032
1234